BioMarin Pharmaceutical | BMRN - 股票



金融业
股票价格
USD
资产
USD 11.72B
现金及等价物
USD 874.01M
销售成本
USD 276.29M
流动资产
USD 3.97B
流动负债
USD 1.66B
债务
USD 1.44B
EBIT
USD 105.61M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 1.2
股本和储备
USD 6.32B
销售毛利
USD 713.42M
债务利息支出
USD 63.3M
利息收入
USD 22.56M
贷款资金
USD 3.53B
市值
USD 12.46B
净收入
USD 44.76M
营业费用
USD 6.32B
营业利润
USD 105.61M
普通股股本
USD 193.54M
PE价格收益
21.07
税前利润
USD 141.2M
销售收入
USD 990M
销售和管理费用
USD 395.55M
股票
USD 1.78B
贸易债权人
USD 913.67M
应收帐款人
USD 1.06B


股票 更改 日
Acadia Pharmaceuticals USD 108.67M 77.1M 2026-06
Agios Pharmaceuticals USD 35.75M 665K 2026-06
Alnylam Pharmaceuticals USD 97.11M 103.04M 2026-06
Amgen USD 6.22B 34M 2026-06
Bayer EUR 11.97B 43M 2026-06
Biogen USD 2.38B 435.3M 2026-06
BioMarin Pharmaceutical USD 1.78B 509.3M 2026-06
Gilead Sciences USD 1.91B 140M 2026-03
Incyte USD 112.54M 3.08M 2026-06
Insmed USD 142.38M 9.48M 2026-06
Ionis Pharmaceuticals USD 50.83M 45.28M 2026-06
Moderna USD 280M 134M 2026-06
Neurocrine Biosciences USD 104.2M 39.7M 2026-06
PTC Therapeutics USD 91.35M 15.79M 2026-06
Puma Biotechnology USD 9.48M 885K 2025-09
Regeneron Pharmaceuticals USD 3.08B 19.3M 2026-06
Roche Holding CHF 7.6B 9M 2025-06
Sanofi EUR 23.5B 812M 2026-03
Sarepta Therapeutics USD 904.27M 96.84M 2026-06
Ultragenyx Pharmaceutical USD 59M 4M 2026-06
United Therapeutics USD 193.8M 15.5M 2026-06
Vertex Pharmaceuticals USD 1.77B 1.6M 2026-06